AI assistant
IMUGENE LIMITED — M&A Activity 2012
Jul 16, 2012
65124_rns_2012-07-16_bee28410-619f-4ddb-916b-ae4ac60b2b3f.pdf
M&A Activity
Open in viewerOpens in your device viewer
17
July 2012
ASX
Announcement Imugene Limited shareholders approve Linguet acquisition
Consegna Group Limited (“Consegna” or “Company”) is pleased to announce that the shareholders of Imugene Limited (ASX:IMU) today approved a resolution to issue 100,000,000 Imugene shares to Consegna as consideration for the acquisition of Lingual Consegna Pty Ltd by Imugene.
Lingual Consegna, a wholly owned subsidiary of Consegna, owns the rights to a family of patents / patent applications that protect the core delivery drug platform (Linguet) that has applications in the human and animal pharmaceutical and nutraceutical industries.
For further information in relation to the proposed transaction please see the Company’s ASX announcement, “Successful Agreement Reached with Imugene for Sale of Linguet”, released to ASX on 1 May 2012.
The Company will make an announcement in regards to the completion of the proposed transaction in due course.
ENDS
For further information , please contact Consegna Group Limited on (03) 9417 5001.
**About
Consegna Group Limited**
Consegna Group Limited’s purpose is to identify, acquire and commercialise late stage therapeutic delivery technologies. The Company targets high value markets and indications using an acquisition strategy driven by strategic value creation, patent protection and realisation criteria. The Company employs a low fixed overhead model with a panel of successful best in field regulatory, intellectual property and scientific advisors.